Randall Michael Giuffre, Director at DiaMedica Therapeutics Inc. (DMAC), bought 819 shares at $1.19 ($975) on 2022-12-01, disclosed to the SEC on 2022-12-05.
Open-market purchase of $975 DMAC by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| Filing → |
| DMAC | BUY | 2022-12-08 | $35K | — | Filing → |
| DMAC | BUY | 2022-12-01 | $136K | — | Filing → |
| DMAC | BUY | 2020-11-23 | $64K | — | Filing → |